Intermittent Imatinib Mesylate in Children with Chronic Myeloid Leukemia: Results and Outcome

Imatinib mesylate (IM) has demonstrated to be highly effective in children with chronic myeloid leukemia (CML). The main issues remain the long-term side effects in pre-pubertal children and the poor compliance in adolescents. The aims of this study were: a) to evaluate the feasibility and efficacy...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2018-11, Vol.132 (Supplement 1), p.4256-4256
Main Authors: Malaspina, Francesco, Putti, Maria Caterina, Santopietro, Michelina, Ladogana, Saverio, Mura, Rosamaria, Burnelli, Roberta, Vacca, Nadia, Rizzo, Lorenzo, Moleti, Maria Luisa, Testi, Anna Maria, Biondi, Andrea, Locatelli, Franco, Saglio, Giuseppe, Foà, Robin, Giona, Fiorina
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imatinib mesylate (IM) has demonstrated to be highly effective in children with chronic myeloid leukemia (CML). The main issues remain the long-term side effects in pre-pubertal children and the poor compliance in adolescents. The aims of this study were: a) to evaluate the feasibility and efficacy of IM given intermittently to molecular responder (MR) CML children in chronic phase (CP), b) to reduce the long-term side effects of MR patients (pts) who started IM in pre-pubertal age, c) to improve compliance of poorly compliant adolescents in major MR (MMR). Among CP-CML pts aged
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-118030